Overview
Title
To establish pharmacy payment and reimbursement by pharmacy benefits managers; to amend title XIX of the Social Security Act to improve prescription drug transparency; and for other purposes.
ELI5 AI
H.R. 9096 is a bill that wants to make sure pharmacies get paid fairly by the middleman companies who help with prescription drugs. It aims to make drug prices clearer and stop these companies from being unfair to both the pharmacies and people buying medicine.
Summary AI
H.R. 9096, the "Pharmacists Fight Back Act," aims to regulate how pharmacy benefits managers (PBMs) pay pharmacies for prescription drugs under federal health care programs. The bill requires PBMs to reimburse pharmacies based on set rules and prohibits actions like overcharging beneficiaries or limiting their pharmacy options. It also seeks to enhance transparency in drug pricing within Medicaid by mandating the reporting of drug prices and ensuring fair reimbursement rates. Additionally, the bill includes penalties for PBMs that violate its provisions.
Published
Keywords AI
Sources
Bill Statistics
Size
Language
Complexity
AnalysisAI
Overview of the Pharmacists Fight Back Act
The "Pharmacists Fight Back Act" is a legislative proposal focused on reforming how pharmacy benefits managers (PBMs) operate, particularly in the context of federal health care programs. The bill aims to enhance transparency, ensure fair reimbursement practices for pharmacies, and prevent certain practices viewed as unfavorable to both beneficiaries and pharmacies.
General Summary of the Bill
The bill primarily addresses three areas:
Pharmacy Payment and Reimbursement: This section outlines obligations for PBMs, including how they must reimburse pharmacies and determine costs for prescription drugs. It establishes rules around calculations of ingredient costs, professional dispensing fees, and cost-sharing for beneficiaries. The bill also sets prohibitions on PBM practices such as steering beneficiaries to certain pharmacies and engaging in spread pricing.
Prohibitions and Enforcement: The bill sets forth various prohibited actions for PBMs. It outlines penalties for violations, which include significant fines and potential imprisonment. It also defines key terms like "rebate," "spread pricing," and "steering" to clarify expectations and limitations on PBM activities.
Prescription Drug Transparency in Medicaid: The bill seeks to improve prescription drug price transparency under Medicaid by broadening the scope of drug pricing surveys and requiring more detailed public reporting. It aims to restrict the use of certain pricing information for setting rates for retail pharmacies.
Significant Issues
Several significant issues and potential challenges are associated with this bill:
Complexity and Clarity: The bill contains complex language, particularly in the definitions of terms and the detailed conditions set out for "in-network pharmacies" and rebate calculations, which might be difficult for smaller pharmacies and PBMs to navigate.
Administrative Burden: Requiring every pharmacy to respond to drug price surveys could impose a substantial administrative load, which smaller pharmacies may find challenging.
Confidentiality Concerns: The push for public transparency of survey data might introduce confidentiality issues, particularly regarding sensitive pricing information such as rebates, potentially leading to competitive disadvantages.
Limitation on Pricing Information: Restrictions on using non-retail pharmacy pricing data for setting retail rates could inadvertently lead to inequitable reimbursement rates that don't fully reflect market conditions.
Broader Public Impact
Broadly, the bill attempts to enhance transparency in drug pricing and protect consumers by regulating PBM practices. This might lead to more predictable and equitable drug pricing, potentially benefiting consumers by lowering their out-of-pocket costs and ensuring fair access to a range of pharmacy services.
However, the complexity of the legislation may create challenges in implementation, especially for smaller pharmacies. The additional administrative requirements could potentially impact their operational efficiency, possibly affecting their ability to compete.
Impact on Specific Stakeholders
Pharmacy Benefits Managers (PBMs): The bill introduces stricter regulations on PBM practices, which might require significant adjustments in their operations. The penalties outlined for non-compliance could also pose substantial risks.
Pharmacies: While the bill aims to ensure fair reimbursement and transparency, smaller pharmacies might struggle with the administrative demands and complexities involved in compliance. Nonetheless, they could benefit from protections against unfair PBM practices.
Healthcare Consumers: Beneficiaries of federal health programs stand to benefit from increased price transparency and potentially reduced costs for prescription drugs, though changes may take time to manifest visibly.
State and Federal Agencies: These bodies might face challenges in implementing and managing the new requirements, especially those concerning data collection and public reporting.
In summary, while the "Pharmacists Fight Back Act" proposes necessary reforms aiming to safeguard pharmacies and consumers, it must balance these objectives with clear, manageable procedures to ensure all stakeholders can adapt effectively without adverse consequences.
Financial Assessment
The "Pharmacists Fight Back Act" presented as H.R. 9096 introduces various financial stipulations that are integral to the regulation of pharmacy benefits managers (PBMs) and their interactions with pharmacies under federal health care programs.
Financial Reimbursements and Penalties
Section 2 outlines specific financial requirements for PBMs regarding how they must reimburse pharmacies:
PBMs must reimburse in-network pharmacies for the ingredient cost of prescription drugs. This reimbursement is based on the national average drug acquisition cost or the wholesale acquisition cost if the drug is not listed in the national index. Additionally, there is an added amount of either 2% of this cost or $25, whichever is less. This structured reimbursement aims to standardize payments and ensure fair financial transactions between PBMs and pharmacies.
PBMs are also required to pay a professional dispensing fee equivalent to what the state pays under title XIX of the Social Security Act, adding another layer of financial protection for pharmacies.
The bill includes severe penalties for PBMs that violate these stipulations. Penalties include fines up to $1,000,000 per violation and imprisonment of up to 10 years. This significant financial and legal risk aims to enforce compliance; however, it might lack tangible compliance measures beyond these punishments.
Transparency and Reporting
Section 3 emphasizes the improvement of drug price transparency under Medicaid. It mandates that all pharmacies respond to surveys regarding drug prices. However, this can become a financial and administrative burden, particularly for smaller pharmacies, impacting their ability to manage resources effectively.
Issues Related to Financial References
One major issue identified is the complexity and technical nature of the language used in defining financial terms, like "rebates" and "spread pricing." Such complexity could lead to misunderstanding or misapplication by smaller PBMs or pharmacies, particularly regarding rebates and financial calculations.
Furthermore, the requirement for public disclosure of survey information could lead to competitive disadvantages, as sensitive financial data, such as rebates and price concessions, may be exposed.
Lastly, the replacement of "retail" with "covered outpatient drug" in Section 3 might introduce confusion, overshadowing financial interpretations and complicating the understanding of reimbursement rates and their financial implications.
Overall, while the bill seeks to create a more equitable and transparent financial environment for pharmacies within federal health care programs, its financial language and conditions may inadvertently pose challenges, especially for smaller entities less equipped to navigate such complexity.
Issues
The language in Section 2 regarding 'in-network pharmacy' contains numerous conditions and references to exclusions, which might be overly complex, potentially leading to difficulties in understanding and compliance, particularly for smaller pharmacies.
Section 2's enforcement mechanism, which includes fines and felony charges for violations, lacks clarity on practical compliance measures, making it potentially difficult to ensure adherence without additional checks beyond legal penalties.
In Section 2, the definitions related to rebates and spread pricing contain highly technical language that could be confusing, potentially leading to misinterpretation or non-compliance by smaller PBMs or pharmacies.
The requirement in Section 3 for every pharmacy in a state to respond to surveys of drug prices could impose a significant administrative burden, especially on smaller pharmacies lacking resources, impacting their operational efficiency.
Section 3's clause on making survey information publicly available could raise confidentiality concerns, particularly about revealing sensitive data such as price concessions and rebates, which could lead to competitive disadvantages.
The consistent replacement of 'retail' with 'covered outpatient drug' in Section 3 might confuse readers not familiar with these definitions, possibly leading to misunderstandings about the bill's scope and effect.
The 'LIMITATION ON USE OF APPLICABLE NON-RETAIL PHARMACY PRICING INFORMATION' clause in Section 3 might limit the equitable determination of reimbursement rates, as it restricts how states can utilize certain pricing data, potentially leading to decisions that do not reflect actual market conditions.
Sections
Sections are presented as they are annotated in the original legislative text. Any missing headers, numbers, or non-consecutive order is due to the original text.
1. Short title Read Opens in new tab
Summary AI
The first section of this bill states that it can be officially referred to as the “Pharmacists Fight Back Act.”
2. Pharmacy payment and reimbursement Read Opens in new tab
Summary AI
The section outlines rules for how pharmacy benefits managers (PBMs) must reimburse pharmacies and calculate costs for prescription drugs under federal health care programs. It details prohibited practices for PBMs, specifies legal consequences for violations, and provides definitions for key terms like "affiliate," "beneficiary," and "steering."
Money References
- (a) In general.—A pharmacy benefits manager (hereinafter referred to as a “PBM”) administering prescription drug benefits on behalf of a Federal health care program, either directly or through an affiliate of such PBM, shall, on behalf of such program— (1) reimburse an in-network pharmacy for the ingredient cost of a prescription drug in an amount equal to the sum of— (A) the national average drug acquisition cost for the drug on the day of claim adjudication (or, in the case of a drug that does not appear on the national average drug acquisition cost index, the wholesale acquisition cost for such prescription drug); and (B) an amount equal to 2 percent of the amount described in subparagraph (A), or $25, whichever is less; (2) pay an in-network pharmacy a professional dispensing fee that is equal to the professional dispensing fee paid by the State in which the pharmacy is located under title XIX of the Social Security Act (42 U.S.C. 1396 et seq.) for dispensing a prescription drug; and (3)(A) subject to subparagraph (B), calculate a beneficiary’s cost sharing requirement for a prescription drug at the point of sale based on a price that is reduced by an amount equal to at least 80 percent of all rebates received in connection with the dispensing of the prescription drug; or (B) in the case of a prescription drug for which the rebate cannot be determined at the point of sale, calculate a beneficiary’s cost sharing requirement for a prescription drug at the point of sale based on a price that is reduced by an amount equal to 80 percent of the lesser of the average aggregate rebate for such drug in the previous calendar year, or the highest possible rebate that can be received for such drug. (b) Prohibited actions.—A PBM administering prescription drug benefits under a Federal health care program shall not— (1) engage in steering; (2) engage in any practice that restricts a beneficiary from using any in-network pharmacy to fill a prescription drug; (3) charge a beneficiary more for a prescription drug than the amount of reimbursement made to the pharmacy that dispenses such drug; (4) require a beneficiary to obtain a brand name prescription drug when a lower cost, AB-rated generic version of such brand name drug is available; (5) engage in spread pricing; (6) lower, impose a fee, or otherwise make an adjustment to a prescription drug claim at the time the claim for such drug is adjudicated, or after the claim is adjudicated, that in any way reduces the amount a pharmacy is reimbursed for such drug pursuant to subsection (a), including a fee charged to a pharmacy even if such fee is not tied to a prescription drug claim; or (7) engage in any practice that bases pharmacy reimbursement for a prescription drug on pharmacy, patient, or any other outcomes, scores, or metrics, provided that nothing shall prohibit pharmacy reimbursement, in addition to reimbursement pursuant to subsection (a), for providing care and services within a pharmacy or a pharmacist’s applicable State scope of practice.
- PBM, or any person acting on behalf of a PBM, that knowingly and willfully violates this Act shall be guilty of a felony and, upon conviction thereof, shall be fined not more than $1,000,000 for each act in violation, or imprisoned for not more than 10 years, or both.
3. Improving prescription drug transparency under the Medicaid program Read Opens in new tab
Summary AI
The section amends the Social Security Act to improve transparency in Medicaid prescription drug pricing by broadening the types of pharmacies included in surveys for drug prices and requiring state reports on them. It mandates that national drug acquisition prices be made public and restricts using non-retail pharmacy pricing data to set rates for retail community pharmacies.